PTC Therapeutics, Inc.: Form 10-K for the period ended Dec 31, 2023
Filed with the SEC on Feb 29, 2024 and accepted by EDGAR at Feb 29, 2024, 16:36 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2023-12-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 12 months2023-01-01 to 2023-12-31 | $937.8m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Research and development | 12 months2023-01-01 to 2023-12-31 | $666.6m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 12 months2023-01-01 to 2023-12-31 | $332.5m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 12 months2023-01-01 to 2023-12-31 | −$439.5m | us-gaap:OperatingIncomeLoss |
| Income tax | 12 months2023-01-01 to 2023-12-31 | −$69.5m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 12 months2023-01-01 to 2023-12-31 | −$626.6m | us-gaap:NetIncomeLoss |
| Diluted EPS | 12 months2023-01-01 to 2023-12-31 | −$8.37 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 12 months2023-01-01 to 2023-12-31 | −$8.37 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 12 months2023-01-01 to 2023-12-31 | 74,838,392 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 12 months2023-01-01 to 2023-12-31 | −$158.4m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 12 months2023-01-01 to 2023-12-31 | $28.4m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2023-12-31 | $594.0m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2023-12-31 | $1.22bn | us-gaap:AssetsCurrent |
| Total assets | At period end2023-12-31 | $1.90bn | us-gaap:Assets |
| Current liabilities | At period end2023-12-31 | $603.1m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2023-12-31 | $2.71bn | us-gaap:Liabilities |
| Long-term debt | At period end2023-12-31 | $284.2m | us-gaap:LongTermDebtNoncurrent |
| Shareholders' equity | At period end2023-12-31 | −$818.6m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001558370-24-002196. Last ingested by Listed: Nov 3, 2026, 09:26 ET. Listed shows no prices and gives no investment advice.